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Background: A seroprevalence study can estimate the percentage of people with SARS-CoV-2 
antibodies in the general population, however, most existing reports have used a convenience 
sample, which may bias their estimates.  
Methods: We sought a representative sample of Connecticut residents, aged ≥18 years and 
residing in non-congregate settings, who completed a survey between June 4 and June 23, 2020 
and underwent serology testing for SARS-CoV-2-specific IgG antibodies between June 10 and 
July 29, 2020. We also oversampled non-Hispanic Black and Hispanic subpopulations. We 
estimated the seroprevalence of SARS-CoV-2-specific IgG antibodies and the prevalence of 
symptomatic illness and self-reported adherence to risk mitigation behaviors among this 
population. 
Results: Of the 567 respondents (mean age 50 [±17] years; 53% women; 75% non-Hispanic 
White individuals) included at the state-level, 23 respondents tested positive for SARS-CoV-2-
specific antibodies, resulting in weighted seroprevalence of 4.0 (90% confidence interval [CI] 
2.0–6.0). The weighted seroprevalence for the oversampled non-Hispanic Black and Hispanic 
populations was 6.4% (90% CI 0.9–11.9) and 19.9% (90% CI 13.2–26.6), respectively. The 
majority of respondents at the state-level reported following risk mitigation behaviors: 73% 
avoided public places, 75% avoided gatherings of families or friends, and 97% wore a facemask, 
at least part of the time. 
Conclusions: These estimates indicate that the vast majority of people in Connecticut lack 
antibodies against SARS-CoV-2 and there is variation by race/ethnicity. There is a need for 
continued adherence to risk mitigation behaviors among Connecticut residents to prevent 
resurgence of COVID-19 in this region. 
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Connecticut was one of the first states in the United States (US) to be severely affected 
by Coronavirus Disease 2019 (COVID-19), with its first confirmed case of COVID-19 in early 
March. While almost 43,000 cases and 4,000 deaths were reported by June,1 a seroprevalence 
study, which estimates the percentage of people with SARS-CoV-2 antibodies, may provide a 
more accurate estimate of the percent of Connecticut population with evidence of a prior 
infection from COVID-19. 
Prior seroprevalence studies have estimated the spread of COVID-19 in the US.2-8 
However, the majority have taken advantage of blood samples collected for other reasons or used 
a convenience sample, which limits their representativeness. The Centers for Disease Control 
and Prevention (CDC) conducted a seroprevalence survey in Connecticut using blood specimens 
collected at commercial laboratories.8 However, these specimens were produced as part of 
routine or sick visit, representing a biased sample. Moreover, this effort did not provide the 
reason for the blood collection nor information about recent symptomatic illness, underlying 
conditions, or relevant risk-mitigation behaviors, which may help predict detection of antibodies 
against SARS-CoV-2.  
Accordingly, with support from the Connecticut Department of Public Health (DPH) and 
the CDC, we conducted the Post-Infection Prevalence (PIP) Study, a public health surveillance 
project to determine the seroprevalence of SARS-CoV-2 among adults residing in community-
non-congregate settings in Connecticut before June. Specifically, we sought to understand prior 
spread at the state-level; collect information about symptomatic illness, risk factors for virus 
infection, and self-reported adherence to risk mitigation behaviors; compare our seroprevalence 
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estimates to available Connecticut estimates; and provide targeted estimates for the non-Hispanic 
Black and Hispanic populations. 
 
METHODS 
Study cohort  
For the state-level seroprevalence estimate, from June 4 to June 23, 2020 we enrolled 735 
adults residing in non-congregate settings (i.e. excluding individuals living in long-term care 
facilities, assisted living facilities, nursing homes, and prisons or jails) in Connecticut, aged ≥18 
years, using a dual-frame Random Digit Dial (RDD) methodology.9 Additionally, from June 23 
to July 22, 2020 we oversampled non-Hispanic Black (n=269) and Hispanic (n=341) individuals 
to provide more accurate estimates for these subpopulations. Details of the sample size 
calculation and RDD methodology are described in eMethods 1. Details of participant 
recruitment are described in eMethods 2. We contacted a total of 7305 respondents at the state-
level, and successfully completed 735 interviews. We contacted a total of 12,508 respondents for 
the oversampled subpopulations, of whom 457 completed interviews. 
The study was deemed not to be research by the Institutional Review Board at Yale 
University because of the public health surveillance activity exclusion and was approved by the 
Institutional Review Board at Gallup. 
 
Survey components 
Individuals selected were provided study details, and informed consent was obtained 
from all participants by trained interviewers. Participants were interviewed using a questionnaire 
that collected information on demographics, social determinants of health, history of influenza-
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like-illness, symptoms experienced, and other COVID-19-related topics. The average survey 
time was 15 minutes. 
 
Specimen collection and serology testing 
Within 24-48 hours of completing the interview, respondents were contacted to schedule 
their blood draw appointment at their nearest Quest Diagnostics Patient Service Center (PSC). 
Up to 5 attempts were made to each household where the participant agreed to be tested. Upon 
confirmation that the participant had completed the test, an incentive payment of $50 was sent as 
a gift card via email or mail. Beginning July 17, 2020, we offered participants an additional $50 
(for a total compensation of $100) to incentivize completion of the serology test. 
Of the 735 participants enrolled in the state-level estimate, 25 participants refused to 
participate when re-contacted for scheduling and 567 participants completed serology testing at 
93 Quest Diagnostics PSCs throughout Connecticut between June 10 and July 29, 2020 (eFigure 
1). Of the total 341 Hispanic and 269 non-Hispanic Black participants enrolled for the 
oversample estimate, 171 and 148 participants, respectively, completed serology testing 
(eFigure 2). The distribution of the timing of the blood draws is shown in eFigure 3.  
Sera was obtained from samples collected in BD Hemogard serum separator tubes. All 
samples were processed at the Quest Diagnostics Marlborough Laboratory. Samples were run at 
room temperature using the primary collection tube. We measured IgG SARS-CoV-2 antibodies 
using Ortho-Clinical Diagnostics Vitros anti-SARS-CoV-2 IgG test, which detects antibodies 
against the spike glycoprotein of the virus.10 Antibody levels were expressed as the ratio of the 
chemiluminescence signal over the cutoff value, with a value ≥1.00 reported as positive.11 The 
Ortho Vitros IgG test had a reported sensitivity and specificity of 90% and 100%, respectively.10 
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We validated the sensitivity of this test in a small subset of SARS-CoV-2 positive patients 
(n=36) with variable disease severity, using reverse transcription polymerase chain reaction 
testing as the gold standard.12 
Additionally, given the concern about the accuracy of serology tests,13 we re-tested the 
negative samples from 5 high risk cities of Connecticut (i.e. Bridgeport, Hartford, New Haven, 
Stamford, and Waterbury) with the Abbott Architect SARS-CoV-2 IgG test that detects 
antibodies aimed at a different SARS-CoV-2 antigen (nucleocapsid protein).14 
Finally, Quest Diagnostics provided results for all SARS-CoV-2 serology tests conducted 
throughout Connecticut in the same time period (i.e. June 10 and July 29, 2020) for comparison. 
 
Statistical analysis  
The sample data were weighted to approximate the Connecticut population (details 
described in eMethods 3). Briefly, the base weight assigned to each completed survey was 
derived as the product of inverse of the probability of selection and non-response adjustment. 
Next, post-stratification weighting adjustments were made to account for residual non-response 
and to match the weighted sample estimates to known population characteristics for 
Connecticut. Post-stratification weighting for state-level sample was carried out using raking (or 
Iterative Proportional Fitting) procedures to adjust for age, gender, race/ethnicity, and education. 
The categories chosen for weighting the oversample subpopulations were different from what 
was used for the state-level adjustments due to lower available sample sizes. To reduce the effect 
of extreme weights on sampling variance, final weights were trimmed. The margin of error 
(MOE) for this study was calculated at the 90% confidence level (CI) taking into consideration 
the design effect introduced by variability of weights on each survey estimate. Overall study 
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design effect as estimated by the Kish approximation equals 1.83, however, it varies by each 
survey estimate.  
Next, the unweighted seroprevalence was calculated for both the overall state-level 
sample and the oversampled non-Hispanic Black and Hispanic subgroups. Finally, we estimated 
the weighted state-level seroprevalence and the MOE of these estimates, both overall and for 
subgroups with sufficient sample size. Subgroups with sample sizes <30 were too small to 
calculate accurate estimates and were thus not reported. We also estimated the MOE at 95% CI 
for the state-level estimates as a secondary outcome. We reported the weighted seroprevalence 
for non-Hispanic Black and Hispanic subgroups separately. 
All statistical analyses were performed using SPSS 24.0 (SPSS, Inc. Chicago, IL) and R 
version 4.0.2. We considered 2-sided P-values <0.05 as statistically significant.  
 
RESULTS 
Population characteristics for the state-level sample 
The final state-level sample included 567 respondents who completed both the survey 
and the serology test. The mean age of the weighted sample was 50.1 (±17.2) years, 53% were 
women, and the majority (75%) were non-Hispanic White individuals. Other weighted and 
unweighted characteristics of the study sample are reported in Table 1. 
Comparison of the unweighted demographic distribution of individuals who completed 
only the survey with those who completed both the survey and the antibody test has been 
provided in eTable 1. While the 2 groups were not significantly different in regional 
representation, a significantly higher number of younger, Hispanic and non-Hispanic Black 
individuals did not complete blood testing. However, our weighted study sample was closer to 
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the target sample in the distribution of subgroups by age, sex, race/ethnicity, education level, and 
health insurance (Table 1). 
 
Symptoms and risk mitigation behaviors at the state-level  
As shown in Table 2, cough, diarrhea, fever, sore throat and new onset loss of taste or 
smell was reported by 18%, 16%, 9%, 10%, and 5% respondents, respectively, at some point 
between March and June. About 16% individuals reported being tested for coronavirus 
previously, and of these, 12% reported testing positive.  
The majority of respondents reported following risk mitigation practices, at least some of 
the time, since March, with 73% reporting having avoided public places and 75% reporting 
having avoided gatherings of family and friends. Notably, 97% respondents reported wearing 
mask outside their home at least part of the time. About 31% of all respondents reported having 
worked from home at least part of the time, representing 57% of working respondents. We 
compared the prevalence of symptomatic illness and risk mitigation behaviors among individuals 
who completed only the survey with those who completed the survey and the antibody test in 
eTable 2.   
 
Seroprevalence of SARS-CoV-2 antibodies at the state-level  
Seroprevalence estimates are shown in Table 3. Overall, 23 respondents tested positive 
for SARS-CoV-2 antibodies, yielding a weighted seroprevalence of 4.0% (90% CI 2.0–6.0). 
Among individuals who reported having symptomatic illness, those with fever, cough, sore 
throat, and diarrhea had a weighted seroprevalence of 32.4% (90% CI 15.1–49.7), 11.4% (90% 
CI 2.8–20.0), 10.3% (90% CI 0.0–21.0), and 6.9% (90% CI 0.0–14.4), respectively. Among the 
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25 individuals who reported loss of taste or smell, 14 individuals tested positive for SARS-CoV-
2-specific antibodies.  
Asymptomatic individuals had significantly lower weighted seroprevalence 0.6% (90% 
CI 0.0–1.3) compared with the overall state estimate, while those with ≥1 and ≥2 symptoms had 
a seroprevalence of 11.3% (90% CI 5.4–17.2) and 16.1% (90% CI 4.9–27.3), respectively (Table 
3). The comparisons between other subgroups and the state estimates are presented in eTable 3. 
Additionally, seroprevalence estimates at 95% MOE have also been shown in eTable 3. 
Among the 143 negative samples from 5 high risk cities of Connecticut that were re-
tested with Abbott Architect serology assay, 142 (99.3%) samples tested negative. Additionally, 
of the total 25,274 antibody tests conducted by Quest Diagnostics in Connecticut during this time 
period, 2072 (8.4%) samples tested positive. Of the 11 respondents who reported testing positive 
for coronavirus, all tested positive for antibodies. 
 
Characteristics and seroprevalence estimates among non-Hispanic Black and Hispanic 
subpopulations 
For the subpopulation estimate, the final sample included 171 Hispanic (39.9 [±15.5] 
years and 51% women) and 148 non-Hispanic Black (46.4 [±13.0] years and 56% women) adults 
(eTable 4). Fever, cough, sore throat, diarrhea, and new loss of taste or smell was reported by 
11%, 17%, 15% 10%, and 8% of Hispanic participants and 4%, 10%, 5%, 4%, and 6% of Black 
participants (Table 4). About 37% of Hispanic and 31% of non-Hispanic Black individuals 
reported receiving a coronavirus test previously and nearly 6% of Hispanic and 4% non-Hispanic 
Black individuals reported testing positive for coronavirus. The prevalence of symptomatic 
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illness and risk mitigation behaviors among individuals who completed only the survey has been 
compared with those who completed both the survey and the antibody test in eTable 5.  
The weighted seroprevalence among the Hispanic and non-Hispanic Black 
subpopulation, derived from both the random state sample and the oversample, was 19.9% (90% 
CI 13.2–26.6) and 6.4% (90% CI 0.9–11.9) respectively. The seroprevalence estimate for the 
Hispanic group was significantly higher than the overall state-level estimate. 
 
DISCUSSION 
Our study primarily shows that despite Connecticut being an early COVID-19 hotspot, 
the vast majority of people in Connecticut lack detectable antibodies to SARS-CoV-2. In 
addition, individuals who reported having symptomatic illness between March and June of 2020 
had higher seroprevalence rates, but over 90% of these individuals did not have SARS-CoV-2-
specific IgG antibodies. Also, a high percentage of people interviewed reported following risk 
mitigation strategies, which may be partly responsible for the reduction in the number of new 
COVID-19 cases being reported in Connecticut. Finally, the Hispanic subpopulation had a higher 
prevalence of SARS-CoV-2-specific antibodies as compared with the overall state-level 
estimate, suggesting that the burden of disease was higher in this subgroup.  
Our findings are consistent with other reports of more selected Connecticut populations. 
The CDC conducted a seroprevalence study using commercial laboratory data and reported a 
seroprevalence of 4.9% (95% CI 3.6-6.5) between April 26 and May 3 and 5.2% (95% CI 3.8–
6.6) between May 21 and May 26 in Connecticut.2,8 However, these estimates were from people 
who had blood specimens tested for reasons unrelated to COVID-19, such as for a routine or sick 
visit, and as such would be expected to be biased higher than estimates for the general 
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population. Similarly, data for all antibody tests conducted by Quest Diagnostics in Connecticut 
between June 10 and July 29, showed a seropositivity rate of 8.4%. Since these estimates were 
also among people who had a serology test done at a commercial laboratory, it is likely that these 
specimens were drawn from individuals who were more likely to suspect prior disease exposure 
than the general population.  
Overall, our findings are consistent with other reports of population-level seroprevalence 
of SARS-CoV-2 in Europe and the US, although the burden of disease in these regions may have 
varied. A recent report from Spain,15 reported a seroprevalence of 4.6% (95% CI 4.3–5.0) and a 
population-based study from Switzerland,16 reported SARS-CoV-2 antibodies in <10% of the 
population. Reports from regions within the US have also shown similar numbers. A recent 
report from Indiana5 found a seropositivity rate of 1.01% (95% CI, 0.76–1.45) and a community 
seroprevalence survey from Atlanta4 estimated seroprevalence of 2.5% (95% CI, 1.4–4.5). Our 
findings of a higher burden of SARS-CoV-2 antibodies among Hispanic subgroups is also 
consistent with prior reports demonstrating that minority populations have been 
disproportionately affected by COVID-19.5,17 
There are several explanations for why our state-level estimates are lower than what one 
might expect given that Connecticut had nearly 43,000 positive cases and 4,000 COVID-19 
deaths by June 1, 2020. First, the majority of those deaths were among residents of congregate 
facilities. Second, the response and serology testing rates may have influenced the result. Only 
7% of those contacted by phone completed the survey and blood test and the recruited population 
differed from the targets. However, this is a standard response rate in studies seeking 
representative populations and was considered in weighting the data. It is also possible that those 
who were more likely to have a positive test failed to complete the blood draw in higher 
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proportions. However, this non-response was taken into account while weighting the sample. 
Third, there is some evidence suggesting a short-lived antibody response, especially among 
individuals with mild or asymptomatic illness,18,19 and it is possible that more people were 
infected who lost antibodies over time. However, recent studies suggest that the decline in this 
timeframe is small and antibody levels can remain stable for up to 120 days,20,21 and all 11 
people who reported receiving a previous coronavirus test in our study tested positive for 
antibodies. Fourth, the accuracy of the serology tests has been a concern.13 However, 99% of the 
negative serology samples from the highest risk regions of Connecticut that we re-tested with 
Abbott Architect serology assay tested negative a second time. 
Nevertheless, our findings are concordant with other studies in indicating that the vast 
majority of the population in Connecticut does not have detectable levels of antibodies against 
SARS-CoV-2. At present, we do not know whether anti-SARS-CoV-2 antibodies confer 
immunity. If such antibodies, as detected by ELISA, are a marker of immunity, then more than 
95% of the people in Connecticut would be susceptible to the virus. Given low infection rates 
over the summer, these general estimates are still reasonable. As such, there is continued need 
for strong public health efforts encouraging Connecticut residents to adhere to risk mitigation 
behaviors so as to prevent a second wave of spread in the region.  
Conclusion 
Our findings indicate that even in one of the early hotspots of the SARS-CoV-2 outbreak 
in the US, most of the population does not have detectable antibodies against SARS-CoV-2, and 
as such, remains vulnerable to infection. Also, there is notable variation by race/ethnicity. People 
likely need to continue to be vigilant about practices that can slow the spread in order to prevent 
resurgence of the virus in these regions.  
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Overall 567 - 567 - 
Age group, years     
18-29 41 7.2% 13.1% 19.9% 
30-44 90 15.9% 26.7% 22.9% 
45-54 113 19.9% 18.6% 17.5% 
55-64 134 23.6% 18.6% 18.1% 
≥65 187 33.0% 23.0% 21.6% 
Sex     
Men 244 43.0% 46.6% 48.1% 
Women 323 57.0% 53.4% 51.9% 
Race/Ethnicity     
Hispanic 49 8.6% 13.0% 14.4% 
Non-Hispanic White 470 82.9% 74.9% 69.4% 
Non-Hispanic Black 37 6.5% 9.6% 9.8% 
Non-Hispanic Asian 9 1.6% 1.2% 4.7% 
Non-Hispanic Other 5 0.9% 1.7% 1.7% 
Education level     
Less than high school 7 1.2% 3.7% 9.3% 
High school or GED 79 13.9% 33.2% 27.4% 
Some college 131 23.1% 23.9% 26.5% 
Bachelor’s degree or more 350 61.7% 39.2% 36.8% 
Income level     
Less than $24,000 40 7.1% 11.3% N/A 
$24,000 to $59,999 104 18.3% 25.0% N/A 
$60,000 to $119,999 178 31.4% 30.1% N/A 
$120,000 or more 195 34.4% 26.8% N/A 
Don’t know/Refused 50 8.8% 6.8% N/A 
Health insurance     
Yes 554 97.7% 95.3% 94.0% 
No 13 2.3% 4.7% 6.0% 
Employment status     
Employed full-time 263 46.4% 45.2% 63.8% 
Employed part-time 56 9.9% 10.0% 
Unemployed 43 7.6% 10.6% 3.5% 
Retired/Student/Homemaker 175 30.9% 25.5% N/A 
Disabled 0 0.0% 0.0% N/A 
Unknown 30 5.3% 8.6% N/A 
Essential job (exempt from 
stay-at-home orders) 
    
Yes 140 24.7% 27.5% N/A 
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No 169 29.8% 24.8% N/A 
Don’t know/Refused/Not 
employed 
258 45.5% 47.7% N/A 
Region/County     
Fairfield 126 22.2% 25.2% 25.8% 
Hartford 157 27.7% 24.1% 24.9% 
Litchfield 42 7.4% 5.5% 5.2% 
Middlesex 34 6.0% 5.0% 4.7% 
New Haven 131 23.1% 24.3% 24.1% 
New London 41 7.2% 7.8% 7.6% 
Tolland 20 3.5% 4.5% 4.4% 
Windham 16 2.8% 3.6% 3.3% 
Type of home     
Mobile home 2 0.4% 1.0% N/A 
Single family house or 
townhouse 
447 78.8% 69.7% N/A 
Apartment or condo 112 19.8% 28.1% N/A 
Group facility 2 0.4% 0.3% N/A 
Don’t know/Refused  4 0.7% 0.9% N/A 
Self-reported health status     
Excellent 177 31.2% 29.7% N/A 
Very good 223 39.3% 32.0% N/A 
Good 128 22.6% 26.9% N/A 
Fair 33 5.8% 9.2% N/A 
Poor 6 1.1% 2.3% N/A 
Chronic conditions     
Diabetes 64 11.3% 12.2% N/A 
Asthma, COPD or another 
lung disease 
63 11.1% 16.7% N/A 
Heart disease 37 6.5% 6.9% N/A 
Cancer 72 12.7% 10.7% N/A 
High blood pressure 171 30.2% 30.5% N/A 
Immune compromised 46 8.1% 8.5% N/A 
Lived in Connecticut in past 
12 weeks 
    
<6 weeks 9 1.6% 1.0% N/A 
6-10 weeks 13 2.3% 1.9% N/A 
11-12 weeks 543 95.8% 96.5% N/A 
Don’t know/Refused 2 0.4% 0.6% N/A 
1 Source for age, sex, race, ethnicity, education, employment, county targets: American Community 
Survey 2018. Source for health insurance: Reference information for health insurance coverage is 
obtained from the Current Population Survey estimates, 2018. Target percentage is based on expected 
proportions for a perfectly random sample, based on credible external sources. 
Abbreviations: COPD, Chronic Obstructive Pulmonary Disease; GED, General Educational 
Development test; N/A, Not Available. 
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Table 2. Prevalence of symptomatic illness, risk factors for possible exposure, and adherence to 







Symptoms    
Fever 43 7.6% 8.7% (±2.7) 
Cough 84 14.8% 18.3% (±3.5) 
Sore throat 54 9.5% 10.1% (±2.7) 
New loss of taste or smell 25 4.4% 4.8 (±2.0) 
Diarrhea 70 12.3% 15.9% (±3.2) 
Risk Factors/Behaviors    
Received coronavirus test 90 15.9% 15.7% (±3.5) 
Tested positive for coronavirus 11 1.9% 1.9% (±1.4) 
Anyone in household (other than 
respondent) had symptoms of 
coronavirus 
54 9.5% 10.2% (±2.7) 
Anyone in household (other than 
respondent) tested positive for 
coronavirus 
16 2.8% 3.7% (±1.8) 
Avoided going to public places, 
such as stores or restaurants 
422 74.4% 72.8% (±4.1) 
Avoided small gatherings of 
people, with family or friends 
426 75.1% 75.3% (±4.0) 
Worked from home (among all 
respondents, regardless of 
employment status) 
223 39.3% 31.4% (±4.1) 
Worn a mask on your face when 
outside your home 
557 98.2% 96.9% (±1.6) 
Traveled by airplane 39 6.9% 6.5% (±2.6) 
Traveled using public 
transportation, such as bus or train 
19 3.4% 5.2% (±2.0) 
Abbreviations: MOE, Margin of Error at the 90% confidence level  
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Table 3. Unweighted and weighted state-level seroprevalence of SARS-CoV-2-specific IgG 
antibodies among adults in Connecticut, overall and by symptoms and risk factors and behaviors. 







Overall 567 23 (4.1%) 4.0% (±2.0) 
Race/Ethnicity    
Hispanic 49 3 (6.1%) 12.8% (±8.0) 
Non-Hispanic White 470 16 (3.4%) 2.7% (±1.7) 
Non-Hispanic Black 37 3 (8.1%) 2.6% (±4.7) 
Non-Hispanic Asian 9 * * 
Non-Hispanic Other 5 * * 
Symptoms    
Fever 43 14 (32.6%) 32.4% (±17.3) 
Cough 84 11 (13.1%) 11.4% (±8.6) 
Sore throat 54 5 (9.3%) 10.3% (±10.7) 
New loss of taste or smell† 25 * * 
Diarrhea 70 5 (7.1%) 6.9% (±7.5) 
Symptoms aggregate    
Asymptomatic 410 5 (1.2%) 0.6% (±0.7%) 
1 or more symptoms 157 18 (11.5%) 11.3% (±5.9) 
2 or more symptoms 67 13 (19.4%) 16.1% (±11.2%) 
Risk Factors/Behaviors    
Received coronavirus test 90 13 (14.4%) 19.5% (±9.5) 
Tested positive for coronavirus † 11 * * 
Anyone in household (other than 
respondent) had symptoms of 
coronavirus 
54 12 (22.2%) 19.8% (±11.8) 
Anyone in household (other than 
respondent) tested positive for 
coronavirus 
16 * * 
Avoided going to public places, 
such as stores or restaurants 
422 17 (4.0%) 4.8% (±2.4) 
Avoided small gatherings of 
people, with family or friends 
426 17 (4.0%) 4.6% (±2.4) 
Worked from home (among all 
respondents, regardless of 
employment status) 
223 14 (6.3%) 4.2% (±2.3) 
Worn a mask on your face when 
outside your home 
557 23 (4.1%) 4.1% (±2.0) 
Traveled by airplane 39 0 (0.0%) 0.0% 
Traveled using public 
transportation, such as bus or train 
19 * * 
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* Sample size is <30 and too small to report. 
† Though the sample size was too small to report seroprevalence estimates, all 11 of these individuals 
tested positive for SARS-CoV-2-specific IgG antibodies. Among the 25 individuals who reported loss 
of taste or smell, 14 individuals tested positive for SARS-CoV-2-specific IgG antibodies. 
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Table 4. Prevalence of symptomatic illness, risk factors for possible exposure, and adherence to social-distancing behaviors since 
March 1, 2020 among non-Hispanic Black and Hispanic subpopulation. 

















Overall 171 N/A N/A 148 N/A N/A 
Symptoms       
Fever 16 9.4% 10.8% (±5.6) 7 4.7% 3.9% (±3.6) 
Cough 31 18.1% 17.4% (±6.4) 18 12.2% 10.1% (±6.4) 
Sore throat 30 17.5% 15.0% (±6.1) 8 5.4% 4.7% (±4.6) 
New loss of taste or smell 15 8.8% 7.8% (±4.3) 8 5.4% 4.2% (±3.8) 
Diarrhea 25 14.6% 10.2% (±5.5) 11 7.4% 5.7% (±4.7) 
Risk Factors/Behaviors       
Received coronavirus test 64 37.4% 36.9 (±9.6) 54 36.5% 31.0% (±10.5) 
Tested positive for coronavirus 
(out of all participants, 
regardless of prior testing) 
10 5.8% 6.2% (±3.8) 9 6.1% 3.9% (±4.7) 
Anyone in household (other 
than respondent) had symptoms 
of coronavirus 
28 16.4% 20.6% (±6.8) 6 4.1% 2.1% (±2.1) 
Anyone in household (other 
than respondent) tested positive 
for coronavirus 
15 8.8% 9.3% (±4.6) 3 2% 2.0% (±2.7) 
Avoided going to public places, 
such as stores or restaurants 
139 81.3% 79.2% (±7.6) 96 64.9% 63.8% (±10.5) 
Avoided small gatherings of 
people, with family or friends 
140 81.9% 81.6% (±6.9) 108 73% 75.4% (±9.2) 
Worked from home (among all 
respondents, regardless of 
employment status) 
42 24.6% 11.8% (±5.7) 48 32.4% 17.8% (±9.0) 
Worn a mask on your face 
when outside your home 
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Traveled by airplane 11 6.4% 4.8% (±3.3) 6 4.1% 4.0% (±4.8) 
Traveled using public 
transportation, such as bus or 
train 
11 6.4% 13.1% (±5.5) 16 10.8% 23.7% (±7.5) 
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